DE60209779T2 - Sulfonamidderivate, deren herstellung und deren verwendung als medikamente - Google Patents

Sulfonamidderivate, deren herstellung und deren verwendung als medikamente Download PDF

Info

Publication number
DE60209779T2
DE60209779T2 DE60209779T DE60209779T DE60209779T2 DE 60209779 T2 DE60209779 T2 DE 60209779T2 DE 60209779 T DE60209779 T DE 60209779T DE 60209779 T DE60209779 T DE 60209779T DE 60209779 T2 DE60209779 T2 DE 60209779T2
Authority
DE
Germany
Prior art keywords
sulfonamide
indol
general formula
methylbenzo
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209779T
Other languages
German (de)
English (en)
Other versions
DE60209779D1 (de
Inventor
Ramon Merce-Vidal
Blas Andaluz-Mataro
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Application granted granted Critical
Publication of DE60209779D1 publication Critical patent/DE60209779D1/de
Publication of DE60209779T2 publication Critical patent/DE60209779T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60209779T 2001-11-14 2002-11-08 Sulfonamidderivate, deren herstellung und deren verwendung als medikamente Expired - Lifetime DE60209779T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200102517A ES2187300B1 (es) 2001-11-14 2001-11-14 Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ES200102517 2001-11-14
PCT/ES2002/000518 WO2003042175A1 (es) 2001-11-14 2002-11-08 Derivados de sulfonamidas, su preparación y su aplicación como medicamentos

Publications (2)

Publication Number Publication Date
DE60209779D1 DE60209779D1 (de) 2006-05-04
DE60209779T2 true DE60209779T2 (de) 2006-11-16

Family

ID=8499446

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60209779T Expired - Lifetime DE60209779T2 (de) 2001-11-14 2002-11-08 Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60232029T Expired - Lifetime DE60232029D1 (de) 2001-11-14 2002-11-08 N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60232029T Expired - Lifetime DE60232029D1 (de) 2001-11-14 2002-11-08 N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems

Country Status (33)

Country Link
US (4) US7105515B2 (enExample)
EP (2) EP1445252B1 (enExample)
JP (2) JP4416505B2 (enExample)
KR (1) KR20040071685A (enExample)
CN (1) CN1271052C (enExample)
AR (1) AR037288A1 (enExample)
AT (2) ATE319684T1 (enExample)
BR (1) BR0214243A (enExample)
CA (1) CA2466965C (enExample)
CO (1) CO5590895A2 (enExample)
CY (1) CY1105362T1 (enExample)
DE (2) DE60209779T2 (enExample)
DK (1) DK1445252T3 (enExample)
EC (1) ECSP045105A (enExample)
ES (4) ES2187300B1 (enExample)
HR (1) HRP20040429B1 (enExample)
HU (1) HUP0402317A2 (enExample)
IL (2) IL161885A0 (enExample)
IS (2) IS7263A (enExample)
MA (1) MA27093A1 (enExample)
MX (1) MXPA04004601A (enExample)
NO (1) NO20042478L (enExample)
NZ (2) NZ533136A (enExample)
PL (1) PL373894A1 (enExample)
PT (2) PT1445252E (enExample)
RS (1) RS41104A (enExample)
RU (2) RU2293082C2 (enExample)
SG (1) SG146442A1 (enExample)
SI (1) SI1445252T1 (enExample)
TW (1) TWI275585B (enExample)
UA (1) UA78252C2 (enExample)
WO (1) WO2003042175A1 (enExample)
ZA (1) ZA200404073B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
AR044275A1 (es) * 2003-05-09 2005-09-07 Esteve Labor Dr Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222830B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222829B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
HRP20090419T1 (hr) * 2004-01-02 2009-09-30 Suven Life Sciences Limited Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2007063418A2 (en) 2005-04-13 2007-06-07 Neuraxon, Inc. Substituted indole compounds having nos inhibitory activity
JP5026690B2 (ja) * 2005-11-21 2012-09-12 株式会社ジャパンディスプレイイースト 表示装置
SI1979314T1 (sl) * 2006-01-24 2013-02-28 Eli Lilly And Company Indol sulfonamidni modulatorji progesteronskih receptorjev
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
JP5350219B2 (ja) * 2006-04-13 2013-11-27 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP1953141A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
EP2020230B1 (en) 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
EP2036888A1 (en) * 2007-09-17 2009-03-18 Laboratorios del Dr. Esteve S.A. Naphthyl-substituted sulfonamides
CA2705833A1 (en) * 2007-11-16 2009-05-22 Subhash C. Annedi 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
BRPI0820632A2 (pt) * 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
EP2116547A1 (en) * 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
EP2116546A1 (en) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
CA2919783C (en) * 2013-08-02 2018-02-06 Pfizer Inc. Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
US6380201B1 (en) * 1997-08-05 2002-04-30 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
CN1599718A (zh) 2005-03-23
MA27093A1 (fr) 2004-12-20
RU2004117850A (ru) 2005-11-20
JP4416505B2 (ja) 2010-02-17
BR0214243A (pt) 2004-12-21
HUP0402317A2 (hu) 2005-02-28
MXPA04004601A (es) 2004-08-13
RU2293082C2 (ru) 2007-02-10
IS8698A (is) 2007-12-05
US20050032791A1 (en) 2005-02-10
US20060258653A1 (en) 2006-11-16
CY1105362T1 (el) 2010-03-03
US7176200B2 (en) 2007-02-13
IS7263A (is) 2004-05-13
US7105515B2 (en) 2006-09-12
ES2187300A1 (es) 2003-05-16
EP1445252B1 (en) 2006-03-08
KR20040071685A (ko) 2004-08-12
JP2005513016A (ja) 2005-05-12
HRP20040429A2 (en) 2005-06-30
CO5590895A2 (es) 2005-12-30
EP1445252A1 (en) 2004-08-11
SG146442A1 (en) 2008-10-30
PT1666462E (pt) 2009-05-07
HK1070053A1 (en) 2005-06-10
IL161885A0 (en) 2005-11-20
ECSP045105A (es) 2004-07-23
US7498328B2 (en) 2009-03-03
EP1666462B1 (en) 2009-04-15
NZ543393A (en) 2007-04-27
JP2009298819A (ja) 2009-12-24
CA2466965A1 (en) 2003-05-22
JP5132649B2 (ja) 2013-01-30
US20030191124A1 (en) 2003-10-09
ZA200404073B (en) 2006-05-31
ES2187300B1 (es) 2004-06-16
NO20042478L (no) 2004-08-12
WO2003042175A1 (es) 2003-05-22
RS41104A (sr) 2006-10-27
ATE428694T1 (de) 2009-05-15
TW200407306A (en) 2004-05-16
DK1445252T3 (da) 2006-06-19
PL373894A1 (en) 2005-09-19
ATE319684T1 (de) 2006-03-15
AR037288A1 (es) 2004-11-03
UA78252C2 (en) 2007-03-15
NZ533136A (en) 2006-01-27
SI1445252T1 (sl) 2006-06-30
EP1666462A1 (en) 2006-06-07
HRP20040429B1 (hr) 2007-10-31
CN1271052C (zh) 2006-08-23
ES2249129A1 (es) 2006-03-16
TWI275585B (en) 2007-03-11
US20070167448A1 (en) 2007-07-19
US7452881B2 (en) 2008-11-18
RU2005136355A (ru) 2007-05-27
PT1445252E (pt) 2006-07-31
DE60232029D1 (de) 2009-05-28
ES2259387T3 (es) 2006-10-01
CA2466965C (en) 2011-09-06
DE60209779D1 (de) 2006-05-04
ES2249129B2 (es) 2007-08-16
IL193234A0 (en) 2009-02-11
ES2322068T3 (es) 2009-06-16

Similar Documents

Publication Publication Date Title
DE60209779T2 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60212841T2 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
DE60122767T2 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
EP2027107B1 (de) 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen
DE60214990T2 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
DE69105659T2 (de) 3-Arylindol- und 3-Arylindazolderivate.
WO2009071687A1 (de) Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
DE69703242T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
US20050065202A1 (en) Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
CN101133034A (zh) 取代吲唑基磺酰胺和2,3-二氢-吲哚基磺酰胺化合物、其制备及在药物中的用途
MX2007007684A (es) Compuestos sustituidos con fenil-piperazina, su preparacion y uso en medicamentos.
WO2009071691A2 (de) Oxindol-derivate und ihre verwendung als medikament
EP2016943B1 (en) Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
JP2009545555A (ja) 置換インダニルスルホンアミド化合物、それらの調製、および薬剤としての使用
DE60206043T2 (de) Neue indolderivate
CN100441180C (zh) 磺酰胺衍生物在制备用于预防和/或治疗食物摄取性疾病的药物中的用途
HK1070053B (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments

Legal Events

Date Code Title Description
8364 No opposition during term of opposition